<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37952347</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2653</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The effect of donepezil hydrochloride on post-COVID memory impairment: A randomized controlled trial.</ArticleTitle><Pagination><StartPage>168</StartPage><EndPage>174</EndPage><MedlinePgn>168-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2023.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0967-5868(23)00239-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-Coronavirus Disease (COVID-19) condition, known as "post-COVID syndrome," is associated with a range of complications persisting even after recovery. Among these complications, cognitive dysfunction, including memory impairment, has been relatively common observed, impacting executive function and quality of life. To date, no approved treatment exists for this specific complication. Therefore, the present clinical trial aimed to investigate the impact of Donepezil Hydrochloride on post-COVID memory impairment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, controlled trial (Approval ID: IRCT20210816052203N1) was conducted, enrolling 25 patients with post-COVID memory impairment. Participants with a history of hospitalization were randomly assigned to either the drug group (n&#xa0;=&#xa0;10) or the control group (n&#xa0;=&#xa0;15). Memory indices were assessed at baseline, one month, and three months later using the Wechsler Memory Scale-Revised test. SPSS software and appropriate statistical tests were employed for data analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The statistical analysis revealed no significant difference in WMS-R subtest and index scores between the drug and control groups at the 4-week and 12-week follow-up periods. However, within the drug group, there was a notable increase in the visual reproduction I and verbal paired associates II subtests during the specified time intervals.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While donepezil 5&#xa0;mg did not exhibit a significant overall increase in memory scales compared to the control group over time, our findings suggest that this medication may exert a positive effect on specific memory subtests. Further research and exploration are warranted to better understand the potential benefits of donepezil in managing post-COVID-related memory impairment.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The study was approved by the Research Ethics Committee of Aja University of Medical Sciences (Approval ID: IR.AJAUMS.REC.1400.125) and registered in the Iranian Registry of Clinical Trials (IRCT) (Approval ID: IRCT20210816052203N1).</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pooladgar</LastName><ForeName>Parham</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: parhampooladgar@sbmu.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakhabakhsh</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Head of Department of Neurology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran. Electronic address: drsakha2013@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soleiman-Meigooni</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taghva</LastName><ForeName>Arsia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cognitive Science and Behavioral Research Center, Aja University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasiri</LastName><ForeName>Malihe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Basic Science Department, School of Nursing &amp; Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darazam</LastName><ForeName>Ilad Alavi</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognitive impairment</Keyword><Keyword MajorTopicYN="N">Donepezil Hydrochloride</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Memory Deficit</Keyword><Keyword MajorTopicYN="N">Post-acuteCOVIDsyndrome</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>12</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37952347</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2023.09.005</ArticleId><ArticleId IdType="pii">S0967-5868(23)00239-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>